BIOXYTRAN, INC
corporate_fare Company Profile
BIOXYTRAN, INC (OTC:BIXT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for BIXT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BIXT spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Bioxytran Q3: $74K Cash, Going Concern, Defaulted Note and New Lawsuit
- Bioxytran Q2 10-Q: Going Concern, $2.69M Loss, CEO Grant
- Bioxytran Reports Functional Gains in First CIDP Patient Treated with PLICID
- Going Concern Warning Reiterated with Short Cash Runway, Increased Losses, and Significant CEO Performance Grant Amidst Dilutive Debt Default
- BIOXYTRAN Faces Severe Going Concern Risk, Needs $30-35M for Trials Amid Dilutive Financing and Internal Control Weaknesses
Financial Snapshot
Short Interest & Short Volume
On November 20, 2026, 24.8% of BIXT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.